Cdc2/cyclin B1 interacts with and modulates inositol 1,4,5-trisphosphate receptor (type 1) functions.

X Li, K. Malathi, O. Krizanova, K. Ondrias, K. Sperber, V. Ablamunits and T. Jayaraman

*J Immunol* 2005; 175:8440; doi: 10.4049/jimmunol.175.12.8440
http://www.jimmunol.org/content/175/12/8440.3

---

**Subscription**  
Information about subscribing to *The Journal of Immunology* is online at: [http://jimmunol.org/subscription](http://jimmunol.org/subscription)

**Permissions**  
Submit copyright permission requests at: [http://www.aai.org/About/Publications/JI/copyright.html](http://www.aai.org/About/Publications/JI/copyright.html)

**Email Alerts**  
Receive free email-alerts when new articles cite this article. Sign up at: [http://jimmunol.org/alerts](http://jimmunol.org/alerts)
CORRECTIONS


In Figure 1, panel C was omitted. The corrected figure is shown below. The error has been corrected in the online version, which now differs from the print version as originally published.

![Corrected figure](image-url)

In the author line, the sequence of the first two authors is reversed. The corrected author line is shown below.

Krishnamurthy Malathi, Xiaogui Li, Olga Krizanova, Karol Ondrias, Kirk Sperber, Vitaly Ablamunits, and Thottala Jayaraman


The fourth author’s name, Cindy Banh, was omitted. The correct list of authors and affiliations is shown below.

Valerie Pasquetto,* Huynh-Hoa Bui,* Rielle Giannino,* Cindy Banh,* Fareed Mirza,† John Sidney,* Carla Oseroff,* David C. Tscharke,‡ Kari Irvine,‡ Jack R. Bennink,‡ Bjoern Peters,* Scott Southwood,§ Vincenzo Cerundolo,§ Howard Grey,* Jonathan W. Yewdell,* and Alessandro Sette*†

*La Jolla Institute for Allergy and Immunology, San Diego, CA 92109; †Tumor Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom; ‡Epimmune Incorporated, San Diego, CA 92121; §Laboratory of Viral Diseases, National Institutes of Health, Bethesda, MD 20892; and †Division of Immunology and Infectious Diseases, Queensland Institute of Medical Research, Herston, Queensland, Australia


In Materials and Methods, in the first sentence under the heading Intranasal administration of recombinant adenovirus-containing HO-1 cDNA, the source for adenoviral HO-1 cDNA was incorrectly attributed. The source is stated in the corrected sentence below.

Mice were anesthetized with methoxyflurane, and then 5 × 10⁸ PFU of adenoviral HO-1 (Ad-HO-1) (a gift from K. Kolls, University of Pittsburgh Medical Center, Pittsburgh, PA, and J. Alam, Alton Ochsner Medical Foundation, New Orleans, LA) (29) or adenoviral β-galactosidase (Ad-LacZ) (BD Biosciences) were administered intranasally to each mouse in a volume of 50 μl as described previously (12).

The authors also wish to add the reference shown below.


In Figure 1, a sentence regarding the solid and broken lines was omitted from the legend. The corrected legend is shown below.

**FIGURE 1.** Specificity of the CM4 mAb. A, YB2 or RNK cells transfected with Ly49 constructs were stained with medium or first layer Abs followed by AF488 goat anti-mouse Ig. Solid lines: staining by CM4. Left broken line: medium control. Right broken line: staining by positive control Abs Ly49A = A1, Ly49B = 1A1, Ly49C = 4D12, Ly49D = 4E5, Ly49E = 4D12, Ly49F = HBF, Ly49G = 4G11, Ly49H = 3D10, Ly49I = YBI. B, Cross-competition between Abs. YB2 cells transfected with Ly49E (YB2-E) and RNK cells transfected with Ly49F (RNK-F) were incubated with medium or saturating quantities of the unlabeled Ly49 Abs shown on the y-axis. After 20 min, AF488-labeled CM4, 4D12, or HBF Ab was added, and incubation was continued for an additional 20 min. Median fluorescence values were determined by flow cytometry, and the percentage inhibition caused by pretreatment with each unlabeled Ab is plotted on the y-axis. The likelihood that the inhibition observed was due to chance variation was determined by Student’s *t* test (*, *p* < 0.05, **, *p* < 0.01, ***, *p* < 0.001). The experiments shown are representative of three similar experiments of each type that were performed.

In Figure 9A, the gel image labeled Ly49A is inverted. The corrected figure is shown below.

Figure 10, demonstrating intracellular trafficking of HLA-DR after the introduction of HIV proteins, is incorrect. The corrected figure is shown below.


In Materials and Methods, in the first sentence under the heading *RSV infection*, the designation of the virus type should be human RSV A strain, not A2 strain.


In Materials and Methods, in the first sentence under the heading *Virus and infection*, the designation of the virus type should be human RSV A strain, not A2 strain.

Figure 3B, demonstrating the apoptotic effect of gp120 on CD4 and CD8 cells; Figure 4B, depicting the apoptotic effect of Fas-FasL interactions in CD4 and CD8 T cells cocultured with 43\textsubscript{HIV} cells; and Figure 6B, showing the apoptotic activity of fractionated supernatant from the 43\textsubscript{HIV} cell line, are inaccurate. The corrected figures are shown below.

![Corrected Figure 3B](http://www.jimmunol.org/)

In Figure 5, demonstrating the inability of HIV-1-infected 43 cells to present antigen to HLA-DR2 and DR4 T cells, panels A and B are the same. The corrected figure is shown below.